Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today reported financial results for the second quarter ended June 30, 2019. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
"We are pleased with our second quarter results and strong business momentum," said Brendan Kennedy, Tilray President and Chief Executive Officer. "Our team has executed against our plan, with adult-use revenue nearly doubling in the second quarter compared to the first quarter and gross margin increasing sequentially for the second quarter in a row. As we continue to grow, we remain focused on our long-term strategic objectives and deploying capital to maximize stockholder value."
Second Quarter 2019 Financial Highlights
|
Three months ended June 30, |
|
Six months ended June 30, |
|
||||||||||||||||||||
|
2019 |
2018 |
$ Change |
|
% Change |
|
2019 |
2018 |
$ Change |
% Change |
|
|||||||||||||
Adult-use |
$ |
15,041 |
$ |
? |
$ |
15,041 |
|
N/A |
|
$ |
22,922 |
$ |
? |
$ |
22,922 |
N/A |
|
|||||||
ACMPR (direct to patient & bulk) |
|
9,078 |
|
9,267 |
|
(189 |
) |
(2 |
)% |
|
16,841 |
|
16,645 |
|
196 |
1 |
% |
|||||||
Food products |
|
19,935 |
|
? |
|
19,935 |
|
N/A |
|
|
25,517 |
|
? |
|
25,517 |
N/A |
|
|||||||
International - medical |
|
1,850 |
|
477 |
|
1,373 |
|
288 |
|
|
3,662 |
|
907 |
|
2,755 |
304 |
|
|||||||
Total revenue |
$ |
45,904 |
$ |
9,744 |
$ |
36,160 |
|
371 |
% |
$ |
68,942 |
$ |
17,552 |
$ |
51,390 |
293 |
% |
|||||||
Excise tax included in revenue |
$ |
3,862 |
$ |
? |
|
3,862 |
|
N/A |
|
$ |
5,776 |
$ |
? |
|
5,776 |
N/A |
|
Business Highlights
1 Announced August 7, 2019
2 Announced July 11, 2019
3 Announced July 23, 2019
4 Announced August 8, 2019
5 Announced July 5, 2019
Conference Call
The Company will host a conference call to discuss these results today at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-489-6528 from the U.S. and 629-228-0736 internationally. A telephone replay will be available approximately two hours after the call concludes through Tuesday, August 27, 2019, by dialing 855-859-2056 from the U.S., or 404-537-3406 from international locations, and entering confirmation code 1489081.
There will also be a simultaneous, live webcast available on the Investors section of the Company's website at www.tilray.com. The webcast will be archived for 30 days.
About Tilray®
Tilray is a global pioneer in cannabis research, cultivation, production and distribution currently serving tens of thousands of patients and consumers in 13 countries spanning five continents.
Forward Looking Statements
This press release contains "forward-looking statements", which may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, including statements regarding our growth potential, the sustainability of growth, demand for our products and the medical and adult-use cannabis markets, anticipated plans for strategic partnerships, and the closing of the downstream merger with Privateer. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading "Risk Factors" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on August 13, 2019, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
Use of Non-U.S. GAAP Financial Measures
To supplement its financial statements, the Company provides investors with information related to Adjusted EBITDA, which is not a financial measure calculated in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). Adjusted EBITDA is calculated as net income (loss) before interest expense, net; other income, net; deferred income tax recovery, current income tax expense; foreign exchange (gain) loss, net; depreciation and amortization expense; stock-based compensation expense; and acquisition and integration expenses. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. The Company believes Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. Management uses Adjusted EBITDA to compare the Company's performance to that of prior periods for trend analyses and planning purposes. Adjusted EBITDA is also presented to the Company's Board of Directors.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Non-U.S. GAAP measures exclude significant expenses that are required by U.S. GAAP to be recorded in the Company's financial statements and are subject to inherent limitations.
TILRAY, INC. |
||||||||||||||||
Condensed Consolidated Statements of Net Loss and Comprehensive Loss |
||||||||||||||||
(in thousands of U.S. dollars, except for share and per share data, unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
Three months ended June 30, |
|
|
Six months ended June 30, |
|
||||||||||
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
Revenue |
|
$ |
45,904 |
|
|
$ |
9,744 |
|
|
$ |
68,942 |
|
|
$ |
17,552 |
|
Cost of sales |
|
|
33,631 |
|
|
|
5,567 |
|
|
|
51,284 |
|
|
|
9,479 |
|
Gross profit |
|
|
12,273 |
|
|
|
4,177 |
|
|
|
17,658 |
|
|
|
8,073 |
|
General and administrative expenses |
|
|
16,465 |
|
|
|
5,342 |
|
|
|
29,262 |
|
|
|
9,487 |
|
Sales and marketing expenses |
|
|
14,366 |
|
|
|
3,305 |
|
|
|
22,187 |
|
|
|
5,568 |
|
Depreciation and amortization expense |
|
|
2,385 |
|
|
|
281 |
|
|
|
4,248 |
|
|
|
503 |
|
Stock-based compensation expense |
|
|
7,585 |
|
|
|
5,601 |
|
|
|
12,891 |
|
|
|
5,632 |
|
Research and development expenses |
|
|
1,528 |
|
|
|
639 |
|
|
|
2,576 |
|
|
|
1,614 |
|
Acquisition and integration expenses |
|
|
2,464 |
|
|
|
? |
|
|
|
6,888 |
|
|
|
? |
|
Operating loss |
|
|
(32,520 |
) |
|
|
(10,991 |
) |
|
|
(60,394 |
) |
|
|
(14,731 |
) |
Foreign exchange (gain) loss, net |
|
|
(1,611 |
) |
|
|
1,358 |
|
|
|
(1,432 |
) |
|
|
2,504 |
|
Interest expense, net |
|
|
8,586 |
|
|
|
497 |
|
|
|
17,331 |
|
|
|
913 |
|
Finance income from ABG Profit Participation Arrangement |
|
|
(212 |
) |
|
|
? |
|
|
|
(347 |
) |
|
|
? |
|
Other income, net |
|
|
(2,035 |
) |
|
|
(76 |
) |
|
|
(4,380 |
) |
|
|
(197 |
) |
Loss before income taxes |
|
|
(37,248 |
) |
|
|
(12,770 |
) |
|
|
(71,566 |
) |
|
|
(17,951 |
) |
Deferred income tax recovery |
|
|
(2,642 |
) |
|
|
? |
|
|
|
(6,419 |
) |
|
|
? |
|
Current income tax expense |
|
|
447 |
|
|
|
63 |
|
|
|
207 |
|
|
|
63 |
|
Net loss |
|
$ |
(35,053 |
) |
|
$ |
(12,833 |
) |
|
$ |
(65,354 |
) |
|
$ |
(18,014 |
) |
Net loss per share - basic and diluted |
|
|
(0.36 |
) |
|
|
(0.17 |
) |
|
|
(0.68 |
) |
|
|
(0.24 |
) |
Weighted average shares used in computation of net loss per share - basic and diluted |
|
|
97,231,839 |
|
|
|
75,000,000 |
|
|
|
96,037,142 |
|
|
|
75,000,000 |
|
Net loss |
|
$ |
(35,053 |
) |
|
$ |
(12,833 |
) |
|
$ |
(65,354 |
) |
|
$ |
(18,014 |
) |
Foreign currency translation gain (loss) |
|
|
2,924 |
|
|
|
(86 |
) |
|
|
2,449 |
|
|
|
(87 |
) |
Unrealized (loss) gain on cash equivalents and investments |
|
|
(762 |
) |
|
|
? |
|
|
|
646 |
|
|
|
? |
|
Other comprehensive income (loss) |
|
|
2,162 |
|
|
|
(86 |
) |
|
|
3,095 |
|
|
|
(87 |
) |
Comprehensive loss |
|
$ |
(32,891 |
) |
|
$ |
(12,919 |
) |
|
$ |
(62,259 |
) |
|
$ |
(18,101 |
) |
TILRAY, INC. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(in thousands of U.S. dollars, except for share and par value data, unaudited) |
||||||||
|
|
|
|
|
|
|
|
|
|
|
June 30, 2019 |
|
|
December 31, 2018 |
|
||
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
184,551 |
|
|
$ |
487,255 |
|
Short-term investments |
|
|
36,323 |
|
|
|
30,335 |
|
Accounts receivable, net of allowance for doubtful accounts of $1,854 and $292, respectively |
|
|
24,612 |
|
|
|
16,525 |
|
Other receivables |
|
|
1,195 |
|
|
|
969 |
|
Inventory |
|
|
75,317 |
|
|
|
16,211 |
|
Prepaid expenses and other current assets |
|
|
36,633 |
|
|
|
3,007 |
|
Total current assets |
|
|
358,631 |
|
|
|
554,302 |
|
Property and equipment, net |
|
|
147,558 |
|
|
|
80,214 |
|
Intangible assets, net |
|
|
331,983 |
|
|
|
4,486 |
|
Goodwill |
|
|
154,954 |
|
|
|
? |
|
Investments |
|
|
23,195 |
|
|
|
16,911 |
|
Deposits and other assets |
|
|
7,810 |
|
|
|
754 |
|
Total assets |
|
$ |
1,024,131 |
|
|
$ |
656,667 |
|
Liabilities |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
24,368 |
|
|
$ |
10,649 |
|
Accrued expenses and other current liabilities |
|
|
151,288 |
|
|
|
14,818 |
|
Accrued obligations under capital lease |
|
|
252 |
|
|
|
470 |
|
Total current liabilities |
|
|
175,908 |
|
|
|
25,937 |
|
Accrued obligations under capital lease |
|
|
9,032 |
|
|
|
8,286 |
|
Deferred tax liability |
|
|
53,624 |
|
|
|
4,424 |
|
Convertible Notes, net of issuance cost |
|
|
425,400 |
|
|
|
420,367 |
|
Total liabilities |
|
$ |
663,964 |
|
|
$ |
459,014 |
|
Stockholders' equity |
|
|
|
|
|
|
|
|
Class 1 common stock ($0.0001 par value, 250,000,000 shares authorized; 16,666,667 shares issued and outstanding) |
|
|
2 |
|
|
|
2 |
|
Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized; 80,690,864 and 76,504,200 shares issued and outstanding, respectively) |
|
|
8 |
|
|
|
8 |
|
Additional paid-in capital |
|
|
526,830 |
|
|
|
302,057 |
|
Accumulated other comprehensive income |
|
|
6,858 |
|
|
|
3,763 |
|
Accumulated deficit |
|
|
(173,531 |
) |
|
|
(108,177 |
) |
Total stockholders' equity |
|
|
360,167 |
|
|
|
197,653 |
|
Total liabilities and stockholders' equity |
|
$ |
1,024,131 |
|
|
$ |
656,667 |
|
|
Three months ended June 30, |
|
Six months ended June 30, |
|
||||||||
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|
||||
Adjusted EBITDA reconciliation: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
$ |
(35,053 |
) |
$ |
(12,833 |
) |
$ |
(65,354 |
) |
$ |
(18,014 |
) |
Depreciation and amortization expense |
|
2,985 |
|
|
671 |
|
|
5,755 |
|
|
1,148 |
|
Stock-based compensation expense |
|
7,585 |
|
|
5,601 |
|
|
12,891 |
|
|
5,632 |
|
Acquisition and integration expenses |
|
2,464 |
|
|
? |
|
|
6,888 |
|
|
? |
|
Foreign exchange (gain) loss, net |
|
(1,611 |
) |
|
1,358 |
|
|
(1,432 |
) |
|
2,504 |
|
Interest expense, net |
|
8,586 |
|
|
497 |
|
|
17,331 |
|
|
913 |
|
Other income, net |
|
(2,035 |
) |
|
(76 |
) |
|
(4,380 |
) |
|
(197 |
) |
Amortization of inventory step-up |
|
1,360 |
|
|
? |
|
|
2,041 |
|
|
? |
|
Deferred income tax recovery |
|
(2,642 |
) |
|
? |
|
|
(6,419 |
) |
|
? |
|
Current income tax expense |
|
447 |
|
|
63 |
|
|
207 |
|
|
63 |
|
Adjusted EBITDA |
$ |
(17,914 |
) |
$ |
(4,719 |
) |
$ |
(32,472 |
) |
$ |
(7,951 |
) |
|
Three months ended June 30, |
|
Six Months Ended June 30, |
|
||||||||
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|
||||
Adjusted net loss reconciliation: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
$ |
(35,053 |
) |
$ |
(12,833 |
) |
$ |
(65,354 |
) |
$ |
(18,014 |
) |
Acquisition and integration expenses |
|
2,464 |
|
|
? |
|
|
6,888 |
|
|
? |
|
Amortization of inventory step-up |
|
1,360 |
|
|
1,358 |
|
|
2,041 |
|
|
? |
|
Adjusted net loss |
$ |
(31,229 |
) |
$ |
(11,475 |
) |
$ |
(56,425 |
) |
$ |
(18,014 |
) |
Adjusted net loss per share - basic and diluted |
|
(0.32 |
) |
|
(0.15 |
) |
|
(0.59 |
) |
|
(0.24 |
) |
Weighted average shares used in computation of adjusted net loss per share - basic and diluted |
|
97,231,839 |
|
|
75,000,000 |
|
|
96,037,142 |
|
|
75,000,000 |
|
These press releases may also interest you
|